Safer Medical Devices – In Vitro Skin Sensitization Testing with Human Relevance and High Accuracy, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss how GARD™skin Medical Device works and why it is highly accurate and human-relevant and how to predict skin sensitizing hazard of materials by testing extractables directly using extraction solvents in accordance with ISO 10993:12. Attendees will learn how customers use the study results in different stages of the product life cycle, for safer products and in line with the 3Rs.

Xtalks Life Science Webinars

Predictive toxicology is a discipline that aims to proactively identify adverse human health and environmental effects in response to chemical exposure. GARD – Genomic Allergen Rapid Detection™ – is a next-generation, animal-free testing framework for assessment and characterization of chemical sensitizers. The GARD platform integrates state-of-the-art technological components, including human immunological cells, specific genomic biomarker signatures and machine learning-assisted classification models.

As a result, the GARD platform provides an accurate, cost-effective and efficient assessment of skin sensitizing capabilities of neat chemicals, complex formulations, mixtures and materials, including finished medical devices. GARD assays are successfully applied throughout the product life cycle of chemical, life science and medical device industries.

The GARD™skin Medical Device assay is an adaptation of SenzaGen’s skin sensitization test for chemicals, GARD™skin. The medical device adaptation enables the medical device industry to perform skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12, thus mimicking the intended use of the device when in contact with skin. The GARD platform is also compatible with a broad selection of solvents, allowing for further analysis of extracts from chemical characterization studies. GARD™skin is currently being validated for regulatory acceptance.

Join experts from SenzaGen Rose-Marie Jenvert PhD, Product Manager GARD applications and in Joshua Schmidt PhD, Business Development Director-Americas in a live webinar on Wednesday, October 21, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Safer Medical Devices – In Vitro Skin Sensitization Testing with Human Relevance and High Accuracy.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website